小胞モノアミントランスポーター2（VMAT2）阻害剤の世界市場レポート 2025年

小胞モノアミントランスポーター2（VMAT2）阻害剤市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR10.3％で18億5,000万米ドルに成長します。予測期間における成長の背景には、神経変性疾患の罹患率の上昇、標的治療の採用拡大、個別化医療への注目の高まり、研究開発への投資の増加、精神疾患や運動障害に対する意識の高まりなどがあります。この期間の主な動向としては、神経学的研究の進展、薬剤製剤の改良、個別化医療・精密医療へのシフト、次世代VMAT2阻害剤の開発、デジタルヘルス技術の統合などが挙げられます。

パーキンソン病の有病率の増加は、小胞モノアミントランスポーター2（VMAT2）阻害剤市場の拡大を促進すると予想されます。パーキンソン病は進行性の神経疾患であり、脳内のドパミン産生細胞の消失により運動障害を引き起こします。パーキンソン病の有病率の増加は、主に人口の高齢化、診断の向上、毒素への曝露などの環境要因、遺伝的要因、疾患に対する認識の高まりに起因しています。VMAT2阻害剤は、ドパミンの放出を調節し、振戦を軽減し、ジスキネジアを抑制することにより、パーキンソン病の症状を管理するのに役立ちます。例えば、2022年12月にParkinson's Foundationは、米国で約9万人がパーキンソン病と診断されたと報告したが、これは従来の推定年間診断数6万人と比べて50％増でした。その結果、パーキンソン病の有病率の上昇がVMAT2阻害剤市場の成長を後押ししています。

VMAT2阻害剤市場の主要企業は、患者のコンプライアンスを改善し、薬物の安定性を高め、治療成果を最適化するために、カプセル剤などの革新的な製剤の開発に注力しています。カプセルは、ゼラチンやHPMCの殻に包まれた固形製剤であり、正確な投与、薬物の安定性の向上、患者の服薬アドヒアランスのサポートにより、VMAT2阻害剤に利益をもたらします。例えば、ニューロクライン・バイオサイエンシズ社は2024年7月、VMAT2阻害剤Ingrezzaの新剤形であるIngrezza Sprinkle（バルベナジン）カプセルを発売しました。本剤は、嚥下困難なハンチントン病に伴う遅発性ジスキネジアおよび振戦の成人患者への投与を容易にするために開発されました。Ingrezza Sprinkle」は、「Ingrezza」と同様の効果的な服用方法を提供しますが、軟らかい食物に振りかけて服用するか、カプセルごと飲み込むことができます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界小胞モノアミントランスポーター2（VMAT2）阻害剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の小胞モノアミントランスポーター2（VMAT2）阻害剤市場：成長率分析
• 世界の小胞モノアミントランスポーター2（VMAT2）阻害剤市場の実績：規模と成長, 2019-2024
• 世界の小胞モノアミントランスポーター2（VMAT2）阻害剤市場の予測：規模と成長, 2024-2029, 2034F
• 世界小胞モノアミントランスポーター2（VMAT2）阻害剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の小胞モノアミントランスポーター2（VMAT2）阻害剤市場薬物によって、実績と予測, 2019-2024, 2024-2029F, 2034F
• テトラベナジン
• デュテトラベナジン
• バルベナジン
• その他の薬物
• 世界の小胞モノアミントランスポーター2（VMAT2）阻害剤市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• その他の政権
• 世界の小胞モノアミントランスポーター2（VMAT2）阻害剤市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界の小胞モノアミントランスポーター2（VMAT2）阻害剤市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ハンチントン病
• 遅発性ジスキネジア
• その他の用途
• 世界の小胞モノアミントランスポーター2（VMAT2）阻害剤市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門クリニック
• その他のエンドユーザー
• 世界の小胞モノアミントランスポーター2（VMAT2）阻害剤市場テトラベナジンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ハンチントン病の治療
• 遅発性ジスキネジアの管理
• トゥレット症候群の治療
• 世界の小胞モノアミントランスポーター2（VMAT2）阻害剤市場、デュテトラベナジンのタイプ別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ハンチントン病舞踏病
• 遅発性ジスキネジアの治療
• 適応外運動障害
• 世界の小胞モノアミントランスポーター2（VMAT2）阻害剤市場、バルベナジンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遅発性ジスキネジアの治療
• トゥレット症候群の調査
• その他の多動性運動障害
• 世界の小胞モノアミントランスポーター2（VMAT2）阻害剤市場その他の医薬品の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 治験中のVMAT2阻害剤
• 運動障害に対する新たな治療法
• 神経疾患における適応外使用

第7章 地域別・国別分析

• 世界の小胞モノアミントランスポーター2（VMAT2）阻害剤市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の小胞モノアミントランスポーター2（VMAT2）阻害剤市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 小胞モノアミントランスポーター2（VMAT2）阻害剤市場：競合情勢
• 小胞モノアミントランスポーター2（VMAT2）阻害剤市場：企業プロファイル
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Otsuka Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Otsuka Pharmaceutical
• Astellas Pharma
• Bausch Health Companies Inc.
• Avantor Inc.
• Sun Pharmaceutical Industries Limited
• Sumitomo Dainippon Pharma
• Dr. Reddy's Laboratories Ltd.
• H. Lundbeck A/S
• Hikma Pharmaceuticals plc
• Lupin Limited
• Neurocrine Biosciences Inc.
• Luye Pharma Group Ltd.
• Ventegra Inc.
• Mitsubishi Tanabe Pharma Corporation
• Biomol GmbH

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 小胞モノアミントランスポーター2（VMAT2）阻害剤市場2029：新たな機会を提供する国
• 小胞モノアミントランスポーター2（VMAT2）阻害剤市場2029：新たな機会を提供するセグメント
• 小胞モノアミントランスポーター2（VMAT2）阻害剤市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

A vesicular monoamine transporter 2 (VMAT2) inhibitor is a drug that blocks VMAT2, a protein responsible for transporting monoamines such as dopamine, serotonin, and norepinephrine into synaptic vesicles for release in the brain. These inhibitors are used to manage neurological and psychiatric disorders by reducing excessive neurotransmitter release, particularly dopamine, and are effective in treating conditions such as tardive dyskinesia, Huntington's disease, and other hyperkinetic movement disorders.

The main drugs in the VMAT2 inhibitor category include tetrabenazine, deutetrabenazine, valbenazine, and others. Tetrabenazine is a well-known VMAT2 inhibitor that treats movement disorders by lowering dopamine levels in the brain. These medications are administered via various routes, including oral and other methods, and are distributed through hospital pharmacies, online pharmacies, and retail pharmacies. They are used for various conditions such as Huntington's disease, tardive dyskinesia, and other movement disorders. The primary end users of these drugs include hospitals, homecare settings, specialty clinics, and other healthcare facilities.

The vesicular monoamine transporter 2 (VMAT2) inhibitor market research report is one of a series of new reports from The Business Research Company that provides vesicular monoamine transporter 2 (VMAT2) inhibitor market statistics, including the vesicular monoamine transporter 2 (VMAT2) inhibitor industry global market size, regional shares, competitors with the vesicular monoamine transporter 2 (VMAT2) inhibitor market share, detailed vesicular monoamine transporter 2 (VMAT2) inhibitor market segments, market trends, and opportunities, and any further data you may need to thrive in the vesicular monoamine transporter 2 (VMAT2) inhibitor industry. This vesicular monoamine transporter 2 (VMAT2) inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The vesicular monoamine transporter 2 (VMAT2) inhibitor market size has grown rapidly in recent years. It will grow from $1.13 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth during the historic period can be attributed to the rising prevalence of movement disorders, an increasing demand for effective treatment options, greater awareness of tardive dyskinesia, a growing geriatric population, and a higher preference for oral formulations.

The vesicular monoamine transporter 2 (VMAT2) inhibitor market size is expected to see rapid growth in the next few years. It will grow to $1.85 billion in 2029 at a compound annual growth rate (CAGR) of 10.3%. The projected growth in the forecast period can be attributed to the rising incidence of neurodegenerative diseases, a growing adoption of targeted therapies, an increasing focus on personalized medicine, more investment in research and development, and heightened awareness of psychiatric and movement disorders. Key trends during this period include advancements in neurological research, improvements in drug formulations, a shift toward personalized and precision medicine, the development of next-generation VMAT2 inhibitors, and the integration of digital health technologies.

The growing prevalence of Parkinson's disease is expected to drive the expansion of the vesicular monoamine transporter 2 (VMAT2) inhibitor market. Parkinson's disease is a progressive neurological disorder that impairs movement due to the loss of dopamine-producing cells in the brain. The increasing prevalence of Parkinson's is primarily attributed to an aging population, improved diagnosis, environmental factors such as exposure to toxins, genetic factors, and increased awareness of the condition. VMAT2 inhibitors help manage Parkinson's symptoms by regulating dopamine release, reducing tremors, and controlling dyskinesia. For example, in December 2022, the Parkinson's Foundation reported that nearly 90,000 people were diagnosed with Parkinson's disease in the U.S., a 50% increase compared to the previous estimate of 60,000 annual diagnoses. As a result, the rising prevalence of Parkinson's disease is propelling the growth of the VMAT2 inhibitor market.

Leading companies in the VMAT2 inhibitor market are focusing on developing innovative formulations such as capsules to improve patient compliance, enhance drug stability, and optimize therapeutic outcomes. Capsules, which are solid dosage forms enclosed in gelatin or HPMC shells, benefit VMAT2 inhibitors by ensuring precise dosing, improving drug stability, and supporting patient adherence. For example, in July 2024, Neurocrine Biosciences Inc. launched Ingrezza Sprinkle (valbenazine) capsules, a new formulation of the VMAT2 inhibitor Ingrezza. This version is designed to facilitate administration for adults with tardive dyskinesia and chorea associated with Huntington's disease who have difficulty swallowing. Ingrezza Sprinkle provides the same effective dosing options as Ingrezza but can be taken by sprinkling the contents onto soft food or swallowing the capsule whole.

In March 2024, Bristol Myers Squibb, a U.S.-based pharmaceutical company, acquired Karuna Therapeutics for $14 billion. This acquisition enables Bristol Myers Squibb to enhance its neurology portfolio by gaining access to Karuna Therapeutics' promising pipeline, including the VMAT2 inhibitor KarXT. KarXT has the potential to address unmet needs in psychiatric disorders such as schizophrenia, expanding Bristol Myers Squibb's therapeutic offerings and accelerating its growth in the neuroscience sector. Karuna Therapeutics is a U.S.-based biopharmaceutical company that specializes in VMAT2 inhibitor treatments.

Major players in the vesicular monoamine transporter 2 (vmat2) inhibitor market are Thermo Fisher Scientific Inc., Eli Lilly and Company, Merck KGaA, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Otsuka Pharmaceutical, Astellas Pharma, Bausch Health Companies Inc., Avantor Inc., Sun Pharmaceutical Industries Limited, Sumitomo Dainippon Pharma, Dr. Reddy's Laboratories Ltd., H. Lundbeck A/S, Hikma Pharmaceuticals plc, Lupin Limited, Neurocrine Biosciences Inc., Luye Pharma Group Ltd., Ventegra Inc., Mitsubishi Tanabe Pharma Corporation, Biomol GmbH.

North America was the largest region in the vesicular monoamine transporter 2 (VMAT2) inhibitor market in 2024. The regions covered in vesicular monoamine transporter 2 (VMAT2) inhibitor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vesicular monoamine transporter 2 (VMAT2) inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vesicular monoamine transporter 2 (VMAT2) inhibitor market consists of sales of products such as deutetrabenazine, valbenazine, and tetrabenazine. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vesicular monoamine transporter 2 (vmat2) inhibitor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for vesicular monoamine transporter 2 (vmat2) inhibitor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vesicular monoamine transporter 2 (vmat2) inhibitor market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drugs: Tetrabenazine; Deutetrabenazine; Valbenazine; Other Drugs
• 2) By Route Of Administration: Oral; Other Administrations
• 3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• 4) By Application: Huntington's Disease; Tardive Dyskinesia; Other Applications
• 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Tetrabenazine: Huntington's Disease Treatment; Tardive Dyskinesia Management; Tourette Syndrome Treatment
• 2) By Deutetrabenazine: Huntington's Disease Chorea; Tardive Dyskinesia Treatment; Off-Label Movement Disorders
• 3) By Valbenazine: Tardive Dyskinesia Treatment; Tourette Syndrome Research; Other Hyperkinetic Movement Disorders
• 4) By Other Drugs: Investigational VMAT2 Inhibitors; Emerging Therapies For Movement Disorders; Off-Label Use In Neurological Conditions
• Companies Mentioned: Thermo Fisher Scientific Inc.; Eli Lilly and Company; Merck KGaA; Teva Pharmaceutical Industries Ltd.; Otsuka Pharmaceutical Co. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Characteristics

3. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Trends And Strategies

4. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Growth Analysis And Strategic Analysis Framework

• 5.1. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Growth Rate Analysis
• 5.4. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Total Addressable Market (TAM)

6. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Segmentation

• 6.1. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tetrabenazine
• Deutetrabenazine
• Valbenazine
• Other Drugs
• 6.2. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Other Administrations
• 6.3. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• 6.4. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Huntington's Disease
• Tardive Dyskinesia
• Other Applications
• 6.5. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users
• 6.6. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Sub-Segmentation Of Tetrabenazine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Huntington's Disease Treatment
• Tardive Dyskinesia Management
• Tourette Syndrome Treatment
• 6.7. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Sub-Segmentation Of Deutetrabenazine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Huntington's Disease Chorea
• Tardive Dyskinesia Treatment
• Off-Label Movement Disorders
• 6.8. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Sub-Segmentation Of Valbenazine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tardive Dyskinesia Treatment
• Tourette Syndrome Research
• Other Hyperkinetic Movement Disorders
• 6.9. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Investigational VMAT2 Inhibitors
• Emerging Therapies For Movement Disorders
• Off-Label Use In Neurological Conditions

7. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Regional And Country Analysis

• 7.1. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

• 8.1. Asia-Pacific Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

• 9.1. China Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Overview
• 9.2. China Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

• 10.1. India Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

• 11.1. Japan Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Overview
• 11.2. Japan Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

• 12.1. Australia Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

• 13.1. Indonesia Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

• 14.1. South Korea Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Overview
• 14.2. South Korea Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

• 15.1. Western Europe Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Overview
• 15.2. Western Europe Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

• 16.1. UK Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

• 17.1. Germany Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

• 18.1. France Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

• 19.1. Italy Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

• 20.1. Spain Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

• 21.1. Eastern Europe Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Overview
• 21.2. Eastern Europe Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

• 22.1. Russia Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

• 23.1. North America Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Overview
• 23.2. North America Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

• 24.1. USA Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Overview
• 24.2. USA Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

• 25.1. Canada Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Overview
• 25.2. Canada Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

• 26.1. South America Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Overview
• 26.2. South America Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

• 27.1. Brazil Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

• 28.1. Middle East Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Overview
• 28.2. Middle East Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

• 29.1. Africa Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Overview
• 29.2. Africa Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Competitive Landscape And Company Profiles

• 30.1. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Competitive Landscape
• 30.2. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Company Profiles
  • 30.2.1. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Otsuka Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Other Major And Innovative Companies

• 31.1. Otsuka Pharmaceutical
• 31.2. Astellas Pharma
• 31.3. Bausch Health Companies Inc.
• 31.4. Avantor Inc.
• 31.5. Sun Pharmaceutical Industries Limited
• 31.6. Sumitomo Dainippon Pharma
• 31.7. Dr. Reddy's Laboratories Ltd.
• 31.8. H. Lundbeck A/S
• 31.9. Hikma Pharmaceuticals plc
• 31.10. Lupin Limited
• 31.11. Neurocrine Biosciences Inc.
• 31.12. Luye Pharma Group Ltd.
• 31.13. Ventegra Inc.
• 31.14. Mitsubishi Tanabe Pharma Corporation
• 31.15. Biomol GmbH

32. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

34. Recent Developments In The Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

35. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market High Potential Countries, Segments and Strategies

• 35.1 Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer